Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide

Triple-negative breast cancer (TNBC) is a highly metastatic and aggressive disease with limited treatment options. Recently, the combination of the immune checkpoint inhibitor (ICI) atezolizumab (anti-PD-L1) with nab-paclitaxel was approved following a clinical trial that showed response rates in at...

Full description

Bibliographic Details
Main Authors: Adam C. Mirando, Akash Patil, Christine I. Rafie, Brian J. Christmas, Niranjan B. Pandey, Vered Stearns, Elizabeth M. Jaffee, Evanthia T. Roussos Torres, Aleksander S. Popel
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1760685